Abstract
As recombinant haematopoietic growth factors have become recognised as valuable adjuncts to traditional chemotherapeutic regimens, new chemotherapeutic approaches made possible by growth factors have become a major area of clinical research. Use of growth factors to mobilise peripheral blood progenitor cells for both allogeneic and autologous transplantation and ex vivo expansion of progenitor celis are the newest areas of cancer research with haematopoietic growth factors. Probably the most important development has been the identification of a platelet growth factor, megakaryocyte growth and development factor (MGDF) or thrombopoietin (TPO). As thrombocytopenia following bone-marrow transplantation or myeloablative chemo- or radiotherapy is a major concern, the importance of a platelet growth factor is enormous. Data have indicated that the use of growth factors in many clinical settings is cost effective, in spite of the high price of biotechnology products, as reduction in the number of infections, use of intravenous antibiotics, days of hospitalisation, and number of platelet transfusions offsets the initial cost of the therapeutics.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
